You are here

obesity

Heart Drugs May Influence Gut Microbiome In Obese People, Says New Study

Heart Drugs May Influence Gut Microbiome In Obese People, Says New Study

Forbes

Flag link:

Will Novo’s big thinking in obesity pay off?

Will Novo’s big thinking in obesity pay off?

EP Vantage

clinical trials

Flag link:

Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs

Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs

Fierce Biotech

Flag link:

Kintai’s obesity drug that works via the gut microbiome moves closer to the clinic

Kintai’s obesity drug that works via the gut microbiome moves closer to the clinic

Fierce Biotech

Kintai Therapeutics

Flag link:

Gene therapy to fend off aging? Buzzy Harvard startup Rejuvenate Bio says it works in mice

Gene therapy to fend off aging? Buzzy Harvard startup Rejuvenate Bio says it works in mice

Fierce Biotech

age-related disease

type 2 diabetes

Flag link:

Highlights: 2019 Cardiometabolic Health Congress, Chicago IL

Highlights: 2019 Cardiometabolic Health Congress, Chicago IL

CP Wire

cardiometabolic health

chronic kidney disease

Flag link:

Highlights: 2019 Cardiometabolic Health Congress, Chicago IL

cardiometabolic health

chronic kidney disease

Flag link:

Novo Nordisk announces obesity digital health tie-up with Noom

Novo Nordisk announces obesity digital health tie-up with Noom

Pharmaforum

Flag link:

J&J dumps Hanmi obesity drug following midphase trials

J&J dumps Hanmi obesity drug following midphase trials

Fierce Biotech

Hanmi Pharmaceutical

Flag link:

Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists

Boehringer Ingelheim, Gubra to develop anti-obesity peptide poly-agonists

Pharmaceutical Business Review

peptide poly-agonists

Boehringer Ingelheim

Flag link:

Even as obesity rates climb, new diabetes cases fall

Even as obesity rates climb, new diabetes cases fall

Stat

Flag link:

FDA approves PureTech’s obesity device Plenity

FDA approves PureTech’s obesity device Plenity

Pharmaforum

PureTech Health

Flag link:

Obalon to lay off half its workforce in retail pivot

Obalon to lay off half its workforce in retail pivot

Mass Device

Flag link:

Merck doubles down on NGM Bio pact but culls obesity drug

Merck doubles down on NGM Bio pact but culls obesity drug

Fierce Biotech

NGM Biopharmaceuticals

Flag link:

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

With Obesity on the Continued Rise in the U.S., More Anti-Obesity Drugs Are Heading for the Market

BioSpace

Flag link:

Obalon Scores Funding on the Heels of Obesity Market Shift

Obalon Scores Funding on the Heels of Obesity Market Shift

Medical Devices and Diagnostics Industry

Flag link:

LNC Therapeutics Acquires Exclusive License for Microbes Potentially Related to Obesity

LNC Therapeutics Acquires Exclusive License for Microbes Potentially Related to Obesity

CP Wire

LNC Therapeutics

Flag link:

Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs

Belviq Study Results May Improve The Fortunes Of Weight-Loss Drugs

Forbes

Flag link:

Novo Nordisk adds to diabetes pipeline with Evotec deal

Novo Nordisk adds to diabetes pipeline with Evotec deal

Fierce Biotech

drug development

small molecule drugs

Flag link:

Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?

Eisai obesity drug Belviq may have an edge with new heart safety data—but to what end?

Fierce Pharma

Flag link:

Pages